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Abstract
Importance—Anemia is common in patients with advanced chronic kidney disease. While the 
treatment of anemia in patients with end-stage renal disease (ESRD) has attracted considerable 
attention, relatively little is known about patterns and trends in the anemia care received by 
patients before initiating maintenance dialysis or pre-emptive kidney transplantation.
Objective—To determine the trends in anemia treatment received by Medicare beneficiaries 
approaching ESRD.
Design—Closed cohort study.
Setting—United States using national ESRD registry data (U.S. Renal Data System).
Participants—466,803 patients aged ≥67 years initiated maintenance dialysis or underwent pre-
emptive kidney transplantation between 1995 and 2010. All eligible patients had uninterrupted 
Medicare (A+B) coverage for >2 years before ESRD.
Exposure—Time, defined as calendar year of incident ESRD.
Main Outcomes and Measures—Use of erythropoiesis-stimulating agents (ESA), intravenous 
iron supplements, and blood transfusions in the two years prior to ESRD; hemoglobin 
concentration at the time of ESRD. We used multivariable modified Poisson regression to estimate 
adjusted utilization prevalence ratios (aPR) with 95% confidence intervals (CI).
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Results—The proportion of incident ESRD patients receiving any ESA in the two years before 
increased from 3.2% in 1995 to a peak of 40.8% in 2007; thereafter, ESA use declined modestly to 
35.0% in 2010 (compared with 1995: aPR=9.9; CI: 9.0–10.7). Among patients who received an 
ESA, median time from first recorded ESA use to ESRD increased from 120 days in 1995 to 337 
days in 2010. Intravenous iron administration increased from 1.2% (1995) to 12.3% (2010; 
aPR=8.7; CI: 7.6–10.1). The proportion of patients receiving any blood transfusions increased 
monotonically from 20.6% (1995) to 40.3% (2010; aPR=1.88; CI: 1.82–1.95). Mean hemoglobin 
concentrations were 9.5 g/dL in 1995, increased to a peak of 10.3 g/dL in 2006, and then declined 
moderately to 9.9 g/dL in 2010.
Conclusions and Relevance—Between 1995 and 2010, older adults approaching ESRD were 
increasingly more likely to be treated with ESAs, to receive intravenous iron, but also more likely 
to be transfused.
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Introduction
Anemia is a hallmark complication of advanced chronic kidney disease (CKD) and a 
consequence of reduced erythropoietin production by the kidneys, among other factors.1 
Using data from the National Health and Nutrition Evaluation Survey III (NHANES; 1988–
1994), Hsu et al. found that even among patients who were relatively iron replete (ferritin ≥ 
100 ng/mL and transferrin saturation ≥ 20%), 46% (95% confidence interval, CI: 33% to 
59%) of men with advanced CKD (creatinine clearance ≤ 30 mL/min) had a hemoglobin 
concentration <12 g/dL and 21% (95% CI: 15% to 27%) of women had a hemoglobin 
concentration <11 g/dL.2 While not specifically ascertained in that study, it is unlikely that a 
sizeable proportion of persons with advanced CKD in the U.S. received any maintenance 
treatment for anemia as only limited treatment options were available and used in patients 
with non-dialysis requiring CKD at the time. Iron dextrans of various molecular weights 
were the only formulations available at that time; relatively few patients with non-dialysis 
requiring CKD used the iron dextrans for fear of anaphylactoid reactions;3, 4 even fewer 
used anabolic steroids, which had also been shown to increase hemoglobin concentrations in 
ESRD.5
Based on its demonstrated ability to raise hemoglobin concentrations and to avoid 
transfusions,6 epoetin alfa (EPO) was approved for use by the U.S. Food and Drug 
Administration (FDA) in 1989 for the treatment of anemia associated with chronic renal 
failure, including patients on dialysis (ESRD) and patients not on dialysis. Comprehensive 
guidelines on the anemia of kidney disease were published by the National Kidney 
Foundation’s Kidney Disease Outcomes Quality Initiative (KDOQI) in 1997 in which 
treatment of anemia using EPO was strongly endorsed, however, mostly based on expert 
opinion about potential clinical benefit beyond erythropoiesis alone.7 Data from patients 
with ESRD indicate increased use of ESAs between 1992 and 2005, while transfusion rates 
declined during that time.8 However, clinical trials that were subsequently published raised 
serious concerns about more intensive treatment of anemia using ESAs in patients with 
Winkelmayer et al. Page 2






















CKD.9–12 Their results led to more critical assessment of targets of ESA treatment, 
including changes in ESA labels, and to reduced use of ESAs in patients with CKD 
requiring dialysis in the most recent years.13 However, little is known about trends in the 
treatment of anemia in patients with CKD not yet requiring dialysis.
We conducted the present study to examine trends in the use of several types of anemia 




Using the United States Renal Data System (USRDS), the national ESRD registry, we 
identified all patients age 67 years or older who initiated dialysis or who underwent 
preemptive kidney transplantation in the continental US, Alaska, or Hawaii between 1995 
and 2010. We restricted the cohort to all patients who, per payor history file, had 
uninterrupted Medicare Part A and B coverage for at least two years prior to ESRD, the 
latter being the study index.
Exposure of Interest
The exposure of interest was calendar year of initiation of treatment for ESRD.
Variables of Interest – Indicators for Anemia Treatment
From two years of Medicare claims prior to initiation of dialysis or receipt of preemptive 
kidney transplantation, we ascertained receipt of several treatments commonly used to treat 
anemia in patients with advanced CKD: erythropoiesis stimulating agents (ESA: epoetin 
alfa, EPO; darbepoetin alfa; DPO), intravenous iron supplements (iron dextran; iron sucrose; 
sodium ferric gluconate; ferumoxytol), and blood transfusions (for specific codes used refer 
to the Technical Appendix; Supplemental Table S1). The timing of the earliest recorded 
receipt of each of these treatments relative to the initiation of ESRD treatment was also 
noted. For blood transfusions, we defined the distinct number of days on which a transfusion 
was administered to each patient (the number of transfusions given on any single day cannot 
be ascertained from claims data). From the Medical Evidence Report (form CMS-2728), we 
ascertained the hemoglobin concentration or hematocrit reportedly present at initiation of 
treatment for ESRD. Hematocrit values were converted into approximate hemoglobin 
concentrations by dividing by 3.
Patient Characteristics
We ascertained the following characteristics from the USRDS patient file: age (on index), 
sex, race (white, black, Asian, other), and (dual) eligibility for Medicaid. We also 
ascertained reported kidney function at dialysis initiation (estimated glomerular filtration 
rate, eGFR), serum albumin, and Quételet’s (body mass) index (BMI) from the Medical 
Evidence Report.
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We additionally identified the following co-morbidities from the Medical Evidence Report 
and from Medicare claims using previously published algorithms:14 diabetes, hypertension, 
heart failure, coronary artery disease, cerebrovascular disease, peripheral vascular disease, 
chronic obstructive pulmonary disease, and cancer. Comorbidities were ascertained in the 
two-year period prior to the index date and were established by at least one inpatient or two 
outpatient claims not on the same day.
Statistical Analysis
We described all patient characteristics by incident year (collapsed into 3 eras: 1995–2000; 
2001–2005; 2006–2010) using medians and interquartile ranges for continuous variables and 
percentages for categorical variables. We then tabulated and/or plotted receipt of each 
category of anemia treatment prior to ESRD over time. We estimated prevalence ratios (PR) 
and their corresponding 95% confidence intervals (CI) using Poisson regression with a 
modified variance to get proper inference.15 This was done (1) without any adjustment; (2) 
with adjustment for demographics; (3) with additional adjustment for presence of diabetes 
and eGFR and BMI at initiation; and (4) with adjustment for all reported comorbidities. The 
third model is reported in the results unless otherwise noted. Year was treated as a 
categorical variable to allow for non-linear changes. The earliest year (1995) served as the 
referent. A priori, we anticipated an increase of utilization of ESAs over time, but then a 
decrease following the publication of two trials questioning the benefit and indicating some 
harm from more aggressive anemia treatment in 2006.10, 11 Therefore, we also conducted 
analyses that used 2007 as the referent year to quantify any changes following the year in 
which important safety information on ESA use in CKD became available. For the same 
reason, we compared the trends for any transfusion use and for number of transfusion days 
between the 2003–2006 and 2007–2010 eras using interrupted time series analyses.16
Certain variables had incomplete data, especially those on eGFR and BMI at ESRD 
incidence. Since missingness for the variables considered for multivariable adjustment 
affected fewer than 10% of patients, we conducted complete case analyses. However, we 
also conducted sensitivity analyses that employed multiple imputation using chained 
equation (MICE package in R) with five imputations to test the robustness of our findings; 
findings were not materially different and are reported in the Technical Appendix 
(Supplemental Tables S2–S4), but not further discussed.
Analyses were performed using SAS software, version 9.2 (SAS Institute, Inc., Cary, NC) 
and R (The R Project for Statistical Computing; Vienna, Austria). The Institutional Review 
Board of Stanford University approved the study.
Results
We identified 702,192 patients ≥67 years of age who initiated treatment for ESRD between 
1995 and 2010. Of those, 471,083 had two years of uninterrupted Medicare fee-for-service 
(Parts A and B) coverage prior to the index date. Additional 4,275 patients were excluded 
who resided outside the continental US, yielding the final cohort of 466,803. Trends in 
patient characteristics over time are illustrated in Table 1. Pertinent to this study of anemia 
and its treatment, patients initiating treatment for ESRD in more recent years did so with 
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more preserved kidney function (i.e., higher eGFR), higher BMI and a more substantial 
degree of comorbidity (diabetes, cerebrovascular, and peripheral artery diseases). Patients 
initiating dialysis in more recent years also had experienced more and earlier care by a 
nephrologist, as previously reported.17
Use of ESAs increased from 3.2% in patients approaching ESRD in 1995 to 40.8% among 
those who did so in 2007; therafter, ESA use plateaued or decreased slightly to 35.0% in 
2010 (Figure 1, Panel A). The proportion using darbepoetin alfa, after its FDA approval in 
2001 and availability of a specific billing code in 2003, increased swiftly and exceeded 46% 
in 2007 (Figure 1, Panel A). Among patients who received an ESA, median time from first 
recorded ESA use to ESRD increased from 120 days in 1995 to 337 days in 2010 (Figure 1, 
Panel B).
When modeling temporal trends in pre-ESRD ESA use (Figure 1, Panel C; Supplemental 
Table S2), compared with 1995, patients initiating treatment for ESRD in 2010 were almost 
10-times (PR: 9.9; 95% CI: 9.0 to 10.7) more likely to have received an ESA. The findings 
were similar after adjustment for demographic characteristics and for eGFR, BMI and the 
prevalence of diabetes at ESRD incidence (Table S2).
Use of intravenous iron supplementation was low while iron dextran remained the only 
treatment option (e.g., 1.3% in 1995) and increased rapidly once sodium ferric gluconate and 
iron sucrose became available (Figure 2, Panel A), which were approved by the FDA in 
1999 and 2000, respectively. The specific intravenous iron formulation used in patients’ 
earliest recorded intravenous iron claim is shown in Figure 2, Panel B. Among patients 
initiating treatment for ESRD in 2010, 12.3% had received intravenous iron in the two years 
before ESRD treatment, a more than 9-fold increase over the 15-year study period (PR: 
9.20; 95% CI: 8.0–10.6; Figure 2, Panel C; Table S3).
Despite more frequent use of ESAs and intravenous iron, the proportion of patients 
receiving at least one transfusion also increased considerably over time (Figure 3, Panel A). 
While 20.6% of patients reaching ESRD in 1995 had received at least one blood transfusion 
in the two years prior to their first ESRD treatment, the proportion increased steadily, 
reaching 40.3% among patients approaching ESRD in 2010. The PR comparing receipt of 
transfusion in patients approaching ESRD in 2010 vs. 1995 was 1.88 (95% CI: 1.82 to 1.95; 
Figure 3, Panel C; Table S4), and was unaffected by differences in case mix or 
multivariable adjustment. These findings were consistent with increases in the cumulative 
number of transfusion days (Figure 3, Panel B). Of note, the slope of the increase in any 
transfusion use or of number of transfusion days was statistically steeper after 2007 (when 
compared with 2003–2006; p<0.001 and p=0.04, respectively).
The proportions of all possible combinations of anemia treatments received prior to ESRD 
in 2010 are shown in Figure 4 (the corresponding can be gleaned from the Technical 
Appendix, Supplemental Figure S1).
During these marked changes in the use of ESAs, IV iron and transfusion, mean hemoglobin 
concentrations were 9.5 g/dL in 1995, increased to a peak of 10.3 g/dL in 2006, and then 
declined to 9.9 g/dL in 2010 (Figure 5). The corresponding fractions of patients with 
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hemoglobin concentrations <8.0 g/dL (the upper value of the 7–8 g/dL range suggested by 
the American Association of Blood Banks for hospitalized patients with relevant symptoms 
or pre-existing cardiovascular disease18) were 17.3%, 5.5%, and 7.0%.
Discussion
We studied treatment patterns for anemia, a common complication of advanced CKD, in a 
national registry of older patients approaching ESRD in the U.S. between 1995 and 2010. 
We found that the use and duration of ESA treatment prior to ESRD increased considerably 
during that era (at least until 2007) along with increasing use of intravenous iron, which 
jointly contributed to significantly, but modestly higher hemoglobin concentrations by the 
time patients reached ESRD. However, almost twice as many patients received blood 
transfusions prior to reaching ESRD, even when accounting for changes in case mix and 
comorbidity over time. Thus, the main objective of ESA treatment that gave rise to its 
original approval – transfusion avoidance – was not consistently met at the population level. 
These findings are in contrast with declining transfusion trends in older patients without 
diagnosed CKD, older patients with diagnosed CKD (mostly of lesser stages) as well as in 
patients of any age receiving dialysis in whom transfusion rates declined between 1992 and 
2004 or 2005.8, 19 The observed doubling over time of the proportion of older patients 
approaching ESRD who received a transfusion may be a consequence of an upward drift in 
practitioners’ hemoglobin transfusion thresholds over the 15 years we studied, which was 
previously shown in patients receiving dialysis,8 or a function of increasing attention to the 
correction of anemia or responsiveness to patients’ reported symptoms. Our findings are also 
compatible with a study of younger patients with CKD insured by United Healthcare 
(Ingenix database) in whom patients who transitioned to ESRD in a given year experienced 
a 2.5-fold increase in transfusion rates between 2002 and 2008.20
Transfusion avoidance is an important clinical goal, especially in patients with advanced 
CKD or ESRD. These patients are particularly prone to hyperkalemia and fluid overload 
resulting in heart failure, both known complications of blood transfusions. Further, repeated 
transfusions can lead to iron overload (in extreme cases hemosiderosis), which was a 
challenging clinical problem in the ESRD population before the approval of epoetin alfa in 
1989.21 In addition, exposure to blood transfusion markedly increases the likelihood of 
allosensitization in patients eligible for kidney transplantation.22 In addition to increasing 
the odds of a positive crossmatch, disqualifying potential donors,23 allosensitization is 
associated with accelerated graft loss, even among patients lucky enough to crossmatch 
negative and receive a kidney.24 With waiting times for kidney transplantation exceeding 
life expectancy in most geographic regions for most middle aged and older patients with 
ESRD, we can ill afford the provision of unnecessary transfusions, as doing so will virtually 
assure that these patients live out their lives on dialysis.
While transfusion avoidance provided the formal reason for the approval and use of ESAs, 
the enthusiastic adoption and use of ESAs may have been mostly grounded in the 
expectation of other clinical benefits. As stated in the introduction to the 1997 KDOQI 
anemia guidelines, “effective treatment of the anemia of [CKD] improves survival, 
decreases mortality, and increases quality of life.”7 The citations listed in support of that 
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statement or in the guideline on target hemoglobin (recommending a target range of 11–12 
g/dL) referred to either studies of (unproven) surrogate endpoints (e.g. left ventricular 
hypertrophy, exercise capacity), or to observational studies associating hemoglobin 
concentration with outcomes whose ability to control for confounding of inherent 
characteristics that differed between individuals who achieved a higher vs. a relatively lower 
hemoglobin concentration was limited. In 2006, revised KDOQI anemia guidelines changed 
their language indicating that “in patients with CKD, [hemoglobin] should be 11.0 g/dL or 
greater. (MODERATELY STRONG RECOMMENDATION)”25 In addition, without 
providing any convincing evidence, a new recommendation suggested that “there is 
insufficient evidence to recommend routinely maintaining [hemoglobin] levels at 13.0 g/dL 
or greater in ESA-treated patients,”25 which was widely interpreted as an expansion to a 11–
13 g/dL hemoglobin target range. Thus, throughout this era ESA utilization was driven by 
expectation of benefit that was unproven in any quality trials of hard study endpoints.
Our study shows that initiation of ESA treatment prior to ESRD reached a peak in 2007 and 
then plateaued or even declined, with hemoglobin concentrations at ESRD also declining 
during that time. This reversion in the long term upward trend reflected providers’ reactions 
to the sobering results from three relatively large randomized trials in patients with moderate 
to advanced (non-dialysis requiring) CKD, published in late 200610, 11 and 2009,12 
respectively, one of which failed to demonstrate any benefit10 and the other two found 
significant (albeit distinct) cardiovascular risks from more aggressive ESA treatment.11, 12 
Interestingly, it appears that the rate of transfusion prior to ESRD accelerated after 2007, 
compared with the slope prior to 2007. This change probably indicates the dueling effects of 
increasingly lenient transfusion thresholds while less aggressive ESA treatment provided 
less of a hemoglobin reserve to these patients. Apparently, providers (nephrologists, 
internists, hospitalists) consider hemoglobin the single most important factor in their 
decisions to transfuse, with clinical factors such as functional status and cardiovascular 
comorbidities playing a much lesser role.26 In patients on dialysis, increases between 2006 
and 2010 in the proportion of patients whose hemoglobin concentration was below 10 g/dL 
have been linked to increased transfusion rates during the same time period, which was 
independent of any other recorded clinical factors.27
Although we found a more than 10-fold increase in the use of intravenous iron over the 15 
years of study, the proportion of patients who received it remained small at roughly 10% in 
2010. The modest use of IV iron in CKD contrasts starkly with the almost universal use of 
intravenous iron in ESA-treated patients on dialysis, where >95% receive IV iron within the 
first 6 months after initiating dialysis.28 Most clinicians prefer oral iron supplementation in 
patients with non-dialysis requiring CKD despite evidence that intestinal iron absorption is 
poor in these patients.28 Intravenous iron is far less convenient in patients with non-dialysis 
requiring CKD than in patients with ESRD, particularly those on hemodialysis, since venous 
cannulation and often, admission to an infusion center is required. Moreover, several 
sessions are required to give “repletion” doses of IV iron for patients with frank iron 
deficiency, and these repeated venous cannulations may compromise creation of 
arteriovenous fistulas or grafts.
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Perhaps the most striking of our findings is the steady increase in transfusion despite the 
broad and consistent use of pharmaceutical agents effective at raising hemoglobin 
concentrations. Ironically, these agents were approved with the goal to reduce dependence 
on blood transfusion, mainly in the ESRD population where the need for such a therapy was 
clearly needed. Indeed, in the ESRD population transfusions have markedly declined since 
the introduction of ESAs.8 For a variety of reasons, the treatment paradigm for anemia 
management in dialysis patients was extended to the pre-ESRD population until evidence 
from randomized trials challenged these practices. As our study demonstrates, the goal of 
transfusion avoidance has not been consistently met in CKD patients not on dialysis, 
perhaps at least in part by increasingly liberal transfusion practices or sicker patients 
approaching dialysis., Furthermore, the use of transfusion in the ESA era was likely driven 
more by a hemoglobin target than by the prevalence of symptomatic anemia. Given these 
other factors, the increasing use of transfusion was not necessarily a failure of ESAs. While 
clinicians may individualize transfusion practices based on patients’ underlying conditions, 
including attempting to balance risks associated with uncorrected anemia and those 
associated with transfusion (as outlined above), clinical practice guidelines, including those 
from the American Association of Blood Banks suggest that transfusion may be used far too 
liberally in this population.18
There are certain limitations of our study that require consideration. We studied a survivor 
cohort of patients who reached and started treatment for ESRD; patients with advanced 
CKD who died from other causes before reaching ESRD, or who reached ESRD and 
declined dialysis or transplantation were not captured in the database. Our cohort was 
further restricted to older patients who possessed Medicare fee-for-service prior to reaching 
ESRD, since information on drug use and transfusion was only available for patients who 
had qualified for Medicare on age or disability grounds prior to reaching ESRD. 
Generalizability to younger patients reaching ESRD is uncertain. The data we had available 
covered only two years prior to treatment for ESRD, so we cannot rule out any additional 
use of ESAs, IV iron and transfusion earlier in patients’ lifetimes. We were unable to define 
and examine trends in the hemoglobin concentration that gave rise to initiation of ESA or 
intravenous iron therapy (or to blood transfusion) as this information was not required to be 
submitted to Medicare with the corresponding billing claims. Since all transfusions given on 
any single day are subsumed in a single procedure code, we were only able to study 
transfusion days, but could not ascertain the actual number of transfusions given. New 
anemia medications approved during the study period had variably short periods of 
availability without a dedicated HCPCS code. However, these time periods were short (few 
weeks to months) and the degree of under-ascertainment is likely small given their new 
introduction into clinical practice. Finally, the strongest response to the accumulating safety 
concerns with ESA use by the FDA did not occur until mid-2011, when ESA labels were 
revised to no longer include a target hemoglobin range and suggested that ESA initiation be 
considered only in patients whose hemoglobin concentrations were below 10 g/dL.29 We 
were unable to study the impact of this FDA action due to the lag time in availability of data.
In conclusion, over 15 years of study, we found a pronounced trend towards more 
aggressive treatment of anemia in older patients approaching ESRD, which included ESA, 
intravenous iron, and broad based use of red blood cell transfusions. All of these were 
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weakly reflected in an increase in hemoglobin concentrations at the time of onset of ESRD. 
While ESA use plateaued and ensuing hemoglobin concentrations declined after 2007, 
following safety concerns about ESA use in patients with CKD, transfusion use appeared to 
increase even more rapidly. In light of the costs of anemia treatments and the safety 
concerns of currently available anemia treatments, identification of safe, effective, and 
economical anemia treatment strategies in patients with CKD and anemia need to be 
identified.
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Figure 1. Trends in Treatment with Erythropoiesis-Stimulating Agents Prior to End-Stage Renal 
Disease
Panel A: Proportion of Patients Having Received Treatment with an Erythropoiesis-
Stimulating Agent (any; epoetin alfa; darbepoetin alfa)
Panel B: Median Time from First Recorded Treatment with an Erythropoiesis-Stimulating 
Agent to End-Stage Renal Disease (in days)
Panel C: Adjusted Prevalence Rates of Erythropoesis-Stimulating Agent Use Prior to End-
Stage Renal Disease (Referent: 1995)
Multivariable model adjusted for age, sex, race, Medicaid (“dual”) eligibility, comorbid 
diabetes, estimated glomerular filtration rate and body mass index at end-stage renal disease.
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Figure 2. Trends in Treatment with Intravenous Iron Supplements Prior to End-Stage Renal 
Disease
Panel A: Proportion of Patients Receiving Any Intravenous Iron
Panel B: Specific Intravenous Iron Formulation Used in the Earliest Available Claim (iron 
dextran; iron sucrose; ferrous gluconate; ferumoxytol)
Panel C: Adjusted Prevalence Ratios of Intravenous Iron Use Prior to End-Stage Renal 
Disease (Referent: 1995)
Multivariable model adjusted for age, sex, race, Medicaid (“dual”) eligibility, comorbid 
diabetes, estimated glomerular filtration rate and body mass index at end-stage renal disease.
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Figure 3. Trends in Blood Transfusion Use Prior to End-Stage Renal Disease
Panel A: Proportion of Patients Receiving Any Blood Transfusion
Panel B: Number of Blood Transfusion Days (1; 2; 3; 4+)
Note: Compared with 2003–2006, the trend lines for transfusion use or number of 
transfusion days accelerated significantly in 2007–2010 (P<0.001 and P=0.04, respectively).
Panel C: Adjusted Prevalence Ratios of Any Blood Transfusion Prior to End-Stage Renal 
Disease (Referent: 1995)
Multivariable model adjusted for age, sex, race, Medicaid (“dual”) eligibility, comorbid 
diabetes, estimated glomerular filtration rate and body mass index at end-stage renal disease.
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Figure 4. Venn Diagrams of Utilization among Anemia Treatments prior to End-Stage Renal 
Disease (2010)
ESA – erythropoiesis-stimulating agents. All numbers correspond to proportion of patients 
who received the corresponding anemia treatment(s) in the two years prior to reaching end-
stage renal disease. The number in the bottom right indicates the proportion of patients who 
did not receive any of the three treatments.
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Figure 5. Mean hemoglobin concentration at start of therapy for end-stage renal disease
Hemoglobin concentration in g/dL. ESRD – end-stage renal disease.
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Table 1








 Patient age (years) 75 (71–80) 76 (72–81) 77 (72–82)
 Female 50.1 48.7 45.9
 Race
  White 75.8 76.6 78.0
  Black 21.1 20.0 18.1
  Asian 2.0 2.3 3.0
  Other 1.1 1.1 0.8
  Missing 0.1 0.1 0.0
 Medicaid (“dual”) beneficiary 18.2 19.7 18.8
Cause of ESRD
 Diabetes 38.3 39.8 38.5
 Hypertension 35.4 36.2 36.8
 Glomerulonephritis 8.0 5.9 5.3
 Other 15.8 16.5 17.7
 Missing 2.5 1.6 1.6
Pre-emptive kidney transplantation 0.1 0.3 0.6
Pre-ESRD Nephrology Care
 Earliest outpatient visit prior to ESRD
  None 47.4 39.5 31.7
  >18 months 16.6 24.5 34.8
  18–12 months 7.3 8.5 8.6
  12–6 months 9.1 9.3 8.8
  <6 months 19.6 18.3 16.2
 Number of outpatient visits in 2 years prior to ESRD 7 (3–17) 8 (3–19) 9 (4–23)
Comorbidities
 Diabetes 56.1 61.2 64.2
 Hypertension 94.2 96.6 98.1
 Heart failure 72.0 71.5 70.1
 Coronary artery disease 46.4 45.5 44.0
 Cerebrovascular disease 33.6 34.9 36.9
 Peripheral artery disease 41.9 42.9 43.6
 Chronic obstructive pulmonary disease 10.1 11.8 13.3
 Cancer 20.9 22.3 24.6
Estimated GFR at ESRD (mL/min per 1.73 m2) 8.2 (6.2–11.0) 9.8 (7.3–13.3) 11.1 (9.3–14.6)
 Missing 7.3 3.5 3.7
Body mass index at ESRD (kg/m2) 24.1 (21.1–27.8) 25.4 (22.2–29.5) 26.4 (23.0–30.9)
 Missing 15.0 2.5 2.9





























Serum albumin at ESRD (g/dL) 3.2 (2.8–3.6) 3.2 (2.7–3.6) 3.2 (2.7–3.6)
 Missing 28.9 27.0 24.8
All values are presented as percent or median (interquartile range).
ESRD – end-stage renal disease; GFR – glomerular filtration rate.
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